2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas
Changho Choi, Sandeep K Ganji, Ralph J DeBerardinis, Kimmo J Hatanpaa, Dinesh Rakheja, Zoltan Kovacs, Xiao-Li Yang, Tomoyuki Mashimo, Jack M Raisanen, Isaac Marin-Valencia, Juan M Pascual, Christopher J Madden, Bruce E Mickey, Craig R Malloy, Robert M Bachoo, Elizabeth A Maher, Changho Choi, Sandeep K Ganji, Ralph J DeBerardinis, Kimmo J Hatanpaa, Dinesh Rakheja, Zoltan Kovacs, Xiao-Li Yang, Tomoyuki Mashimo, Jack M Raisanen, Isaac Marin-Valencia, Juan M Pascual, Christopher J Madden, Bruce E Mickey, Craig R Malloy, Robert M Bachoo, Elizabeth A Maher
Abstract
Mutations in isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) have been shown to be present in most World Health Organization grade 2 and grade 3 gliomas in adults. These mutations are associated with the accumulation of 2-hydroxyglutarate (2HG) in the tumor. Here we report the noninvasive detection of 2HG by proton magnetic resonance spectroscopy (MRS). We developed and optimized the pulse sequence with numerical and phantom analyses for 2HG detection, and we estimated the concentrations of 2HG using spectral fitting in the tumors of 30 subjects. Detection of 2HG correlated with mutations in IDH1 or IDH2 and with increased levels of D-2HG by mass spectrometry of the resected tumors. Noninvasive detection of 2HG may prove to be a valuable diagnostic and prognostic biomarker.
Figures
References
- Balss J, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116:597–602.
- Yan H, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765–773.
- Dang L, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739–744.
- Figueroa ME, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18:553–567.
- Christensen BC, et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst. 2011;103:143–153.
- Parsons DW, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807–1812.
- Von Deimling A, Korshunov A, Hartmann C. The next generation of glioma biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations. Brain Pathology. 2011;21:74–87.
- Bottomley PA. US Patent. United States: 1984. Selective volume method for performing localized NMR spectroscopy. Vol. 4 228.
- Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R. Simultaneous in vivo spectral editing and water suppression. NMR Biomed. 1998;11:266–272.
- Bal D, Gryff-Keller A. 1H and 13C NMR study of 2-hydroxyglutaric acid and lactone. Magnetic Resonance Chemistry. 2002;40:533–536.
- Krawczyk H, Gradowska W. Characterisation of the 1H and 13C NMR spectra of N-acetylaspartylglutamate and its detection in urine from patients with Canavan disease. J Pharm Biomed Anal. 2003;31:455–463.
- Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 2000;13:129–153.
- Ernest RR, Bodenhausen G, Wokaun A. Principles of nuclear magnetic resonance in one and two dimensions. Oxford: Clarendon Press; 1987.
- Thompson RB, Allen PS. Sources of variability in the response of coupled spins to the PRESS sequence and their potential impact on metabolite quantification. Magn Reson Med. 1999;41:1162–1169.
- Choi C, et al. Improvement of resolution for brain coupled metabolites by optimized (1)H MRS at 7T. NMR Biomed. 2010;23:1044–1052.
- Gillies RJ, Raghunand N, Garcia-Martin ML, Gatenby RA. pH imaging. A review of pH measurement methods and applications in cancers. IEEE Eng Med Biol Mag. 2004;23:57–64.
- Griffiths JR. Are cancer cells acidic? Br J Cancer. 1991;64:425–427.
- McLean LA, Roscoe J, Jorgensen NK, Gorin FA, Cala PM. Malignant gliomas display altered pH regulation by NHE1 compared with nontransformed astrocytes. Am J Physiol Cell Physiol. 2000;278:C676–C688.
- Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30:672–679.
- Mlynarik V, Gruber S, Moser E. Proton T (1) and T (2) relaxation times of human brain metabolites at 3 Tesla. NMR Biomed. 2001;14:325–331.
- Traber F, Block W, Lamerichs R, Gieseke J, Schild HH. 1H metabolite relaxation times at 3.0 tesla: Measurements of T1 and T2 values in normal brain and determination of regional differences in transverse relaxation. J Magn Reson Imaging. 2004;19:537–545.
- Ganji SK, et al. T2 measurement of J-coupled metabolites in the human brain at 3T. NMR Biomed. 2011 In Press.
- Norton WT, Poduslo SE, Suzuki K. Subacute sclerosing leukoencephalitis. II. Chemical studies including abnormal myelin and an abnormal ganglioside pattern. J Neuropathol Exp Neurol. 1966;25:582–597.
- Keevil SF, et al. Absolute metabolite quantification by in vivo NMR spectroscopy: II. A multicentre trial of protocols for in vivo localised proton studies of human brain. Magn Reson Imaging. 1998;16:1093–1106.
- Tong Z, Yamaki T, Harada K, Houkin K. In vivo quantification of the metabolites in normal brain and brain tumors by proton MR spectroscopy using water as an internal standard. Magn Reson Imaging. 2004;22:1017–1024.
- Sener RN. L-2 hydroxyglutaric aciduria: proton magnetic resonance spectroscopy and diffusion magnetic resonance imaging findings. J Comput Assist Tomogr. 2003;27:38–43.
- Goffette SM, et al. L-2-Hydroxyglutaric aciduria: clinical, genetic, and brain MRI characteristics in two adult sisters. Eur J Neurol. 2006;13:499–504.
- Choi C, et al. Measurement of glycine in the human brain in vivo by (1) H-MRS at 3 T: application in brain tumors. Magn Reson Med. 2011
- Maher EA, et al. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res. 2006;66:11502–11513.
- Rakheja D, Mitui M, Boriack RL, DeBerardinis RJ. Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors. Pediatr Blood Cancer. 2011;56:379–383.
- Rakheja D, et al. Papillary thyroid carcinoma shows elevated levels of 2-hydroxyglutarate. Tumour Biol. 2011;32:325–333.
Source: PubMed